VanEck Pharmaceutical ETF
| 86,04USD | 0,07USD | 0,08% |
Nettoinventarwert (NAV)
| 102,63 USD | 1,86 USD | 1,85 % |
|---|
| Vortag | 100,77 USD | Datum | 15.12.2025 |
Anlagepolitik
So investiert der VanEck Pharmaceutical ETF: The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index.
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
VanEck Pharmaceutical ETF aktueller Kurs
| 86,04 EUR | 0,07 EUR | 0,08 % |
|---|
| Datum | 17.12.2025 21:56:01 |
| Vortag | 85,97 EUR |
| Börse | Berlin |
Rating für VanEck Pharmaceutical ETF
| €uro FondsNote | - |
Fonds Performance: VanEck Pharmaceutical ETF
| Performance 1 Jahr | 19,42 | |
| Performance 2 Jahre | 35,47 | |
| Performance 3 Jahre | 39,76 | |
| Performance 5 Jahre | 70,06 | |
| Performance 10 Jahre | 91,47 |
Fundamentaldaten
| Valor | A1JRLN |
| ISIN | US92189F6925 |
| Name | VanEck Pharmaceutical ETF |
| Fondsgesellschaft | VanEck |
| Aufgelegt in | United States |
| Auflagedatum | 20.12.2011 |
| Kategorie | Health |
| Währung | USD |
| Volumen | |
| Depotbank | State Street Bank & Trust Co |
| Zahlstelle | |
| Fondsmanager | Peter H. Liao, Griffin Driscoll |
| Geschäftsjahresende | 30.09. |
| Berichtsstand | 16.12.2025 |
Konditionen
| Ausgabeaufschlag | % |
| Verwaltungsgebühr | % |
| Depotbankgebühr | % |
| VL-fähig? | Nein |
| Mindestanlage | |
| Ausschüttung | Ausschüttend |